Alethia is currently focusing on cancer-associated epithelial-to-mesenchymal transition with it AB-16B5 monoclonal antibody, a clinical stage EMT inhibitor to prevent chemotherapy resistance and metastatic tumour invasion.
AB-16B5 – EMT inhibitor
- Alethia is developing an inhibitor of EMT for the treatment of invasive carcinomas. AB-16B5 is a humanized IgG2 antibody against an EMT-inducing form of secreted clusterin (sCLU). AB-16B5 very efficiently blocks EMT and pre-clinical data indicate that animals xenografted with various carcinoma cells show an increase of response to standard of care chemotherapy as well as a reduction of invasion. Read more about AB-16B5